6 matches for your search in the start-up spotlight
rss
Max Delbrück Centre and biotech start-up AlgenScribe cooperate
29-Jul-2024
The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. A special kind of ...
Start-up develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies
28-May-2024
Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic. Captain T Cell GmbH announced the successful ...
Start-up aims to develop the drug for the market
11-Jan-2024
Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the ...
Fighting cancer with specially equipped T cells
04-Oct-2023
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently ...
Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process
01-Aug-2023
To help bring therapies for rare muscle diseases in children to market sooner, the Berlin-based start-up MyoPax, a spin-off from the Max Delbrück Center and Charité – Universitätsmedizin Berlin, has now received a boost from the U.S. Food and Drug Administration (FDA). The company has been ...
Million euro support for MyoPax
22-Sep-2022
MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previously incurable muscle diseases using its innovative muscle stem cell technology. The BioInnovation ...
